{"gene":"COL4A3","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1996,"finding":"Knockout of COL4A3 in mice results in absence of the α3, α4, and α5(IV) collagen chains from the glomerular basement membrane (GBM), with persistence of α1 and α2 chains, demonstrating that COL4A3 is required for assembly of the α3α4α5(IV) network in the GBM. Loss causes progressive glomerulonephritis with GBM multilamination, fibronectin/HSPG/laminin-1/entactin accumulation, and end-stage renal disease.","method":"COL4A3 knockout mouse; immunofluorescence; transmission electron microscopy; Northern blot","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with multiple orthogonal methods (IF, TEM, Northern blot), replicated across subsequent studies","pmids":["8956999"],"is_preprint":false},{"year":1999,"finding":"Deletion of exons 1–12 of Col4a4 together with exons 1–2 of the adjacent Col4a3 and the intergenic promoter abolishes transcription and protein expression of both chains, confirming that the two genes share a bidirectional promoter and that both α3 and α4 chains are individually required for GBM integrity; loss of both accelerates disease onset compared with loss of α3 alone.","method":"Transgenic insertional knockout (OVE250 line); FISH mapping; RT-PCR; immunostaining; electron microscopy","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ablation confirmed by molecular and histological methods; compared to single-gene KO","pmids":["10534397"],"is_preprint":false},{"year":1998,"finding":"COL4A3 and COL4A4 are arranged head-to-head on chromosome 2q36, sharing a bidirectional promoter region enriched in CpG dinucleotides, GC boxes, CTC boxes, and a CCAAT box but lacking a TATA box; transcription start sites for each gene were mapped by RACE and RNase protection assays.","method":"Genomic cloning; RACE; RNase protection assay; nucleotide sequence analysis","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct experimental mapping of transcription start sites and promoter architecture, single lab with multiple orthogonal methods","pmids":["9537506"],"is_preprint":false},{"year":2003,"finding":"Expression of human COL4A3 (via YAC transgene) in Col4a3-/- mice restores co-assembly of the α3/α4/α5(IV) heterotrimer specifically at sites of human α3(IV) expression, rescues GBM function, and reverses the Alport phenotype. This demonstrates that expression of all three chains is required for network assembly and that defective assembly is the pathogenic mechanism.","method":"YAC transgenic rescue in Col4a3-/- mice; immunofluorescence; histology; functional renal assessment","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in-vivo reconstitution with human transgene rescuing KO phenotype, multiple orthogonal readouts","pmids":["14507670"],"is_preprint":false},{"year":2006,"finding":"In Col4a3-/- mice, loss of the α3/α4(IV) chains from the GBM induces ectopic deposition of α5/α6(IV) collagen; the degree of this compensatory isoform switch is strain-dependent (abundant in C57BL/6, near-absent in 129X1/Sv) and correlates with ~46% longer renal survival, revealing a functional substitution capacity of α5α6(IV) for the absent α3α4α5(IV) network.","method":"Col4a3-/- mouse on multiple genetic backgrounds; immunofluorescence; survival analysis; X-linked inheritance analysis in F1 crosses","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mouse strains, genetic crosses, immunohistochemistry, replicated functional outcome","pmids":["16769745"],"is_preprint":false},{"year":1995,"finding":"A G-to-T transversion in COL4A3 intron V activates a cryptic splice acceptor within an antisense Alu element, causing insertion of a 74-bp Alu-derived sequence into the COL4A3 mRNA, disrupting the open reading frame and causing autosomal recessive Alport syndrome.","method":"mRNA screening; RT-PCR; direct sequencing; family segregation analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mRNA-level confirmation of splice-mediated Alu insertion with family segregation; mechanistically defined","pmids":["7633417"],"is_preprint":false},{"year":2000,"finding":"A COL4A3 splice site mutation causing skipping of exon 21 (in-frame deletion, NC domain intact) produces a COL4A3 chain predicted to be incorporated into the triple helix and exert a dominant-negative effect, establishing the molecular basis for autosomal dominant Alport syndrome.","method":"Nested RT-PCR; DHPLC; DNA sequencing; family segregation","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, mRNA-level confirmation of exon skipping; dominant-negative mechanism inferred from structural prediction, not reconstituted in vitro","pmids":["11044206"],"is_preprint":false},{"year":1995,"finding":"A 7-bp deletion in exon 5 of COL4A3 predicts truncation of the α3(IV) chain with loss of 222 amino acids from the carboxy-terminal NC1 domain; the truncated chain is predicted unable to form trimers, and the loss of the Goodpasture epitope (residing in the NC1 domain) is proposed to underlie post-transplant anti-GBM nephritis.","method":"PCR amplification and sequencing of COL4A3 exon 5; parental heterozygosity confirmed by sequencing","journal":"Journal of the American Society of Nephrology : JASN","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — sequence-based mechanism inference confirmed by family analysis; trimer-assembly failure and epitope loss are inferred, not biochemically reconstituted","pmids":["7780062"],"is_preprint":false},{"year":1995,"finding":"Post-transplant alloantibodies in an autosomal recessive Alport patient with a COL4A3 mutation (predicted loss of 85% of the α3(IV) NC1 domain) target primarily the α3(IV) collagen chain, the same epitope targeted in X-linked Alport patients with COL4A5 deletions, demonstrating that absence of α3(IV) from the GBM (whether from failed synthesis or failed assembly) leads to loss of immunological tolerance to the α3(IV) NC1 domain.","method":"Recombinant type IV collagen domain binding assays; characterization of alloantibody specificity using GBM constituents","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — recombinant domain binding assay identifying alloantibody target; single lab, two orthogonal methods","pmids":["7783419"],"is_preprint":false},{"year":2014,"finding":"Collagen receptors DDR1 and integrin α2β1 regulate maturation of the GBM. In the Col4a3-/- Alport model, loss of integrin α2β1 (COL4A3-/-/ITGA2-/- double KO) reduces proteinuria, lowers blood urea nitrogen, extends lifespan by ~20%, decreases glomerular and tubulointerstitial matrix deposition, and normalises elevated MMP2/9/12 and TIMP1 levels, demonstrating that integrin α2β1-mediated collagen signalling drives fibrosis progression.","method":"Double-knockout mouse model; electron microscopy; MMP/TIMP expression analysis; survival and functional readouts","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in double-KO mice with multiple functional and molecular readouts; mechanistic pathway placement","pmids":["24480069"],"is_preprint":false},{"year":2014,"finding":"In cultured podocytes transfected with mutant COL4A3 chains, mutant collagens are retained intracellularly and differentially activate the unfolded protein response (UPR) cascade, implicating ER stress as a modulator of phenotypic severity in COL4A3 nephropathy.","method":"Transfection of podocytes with wild-type or mutant COL4A3; UPR pathway analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cell culture transfection with functional UPR readout; single lab, single method type","pmids":["25514610"],"is_preprint":false},{"year":2019,"finding":"COL4A3 expressed specifically in endothelial cells of Col4a3-/- mice (using an inducible endothelial-specific transgene) does not produce detectable collagen α3α4α5(IV) in the GBM and does not rescue the Alport phenotype, establishing that endothelial cells do not express the Col4a3/a4/a5 genes and are not a viable target for gene therapy.","method":"Endothelial cell-specific inducible transgenic expression in Col4a3-/- mice; immunofluorescence; phenotype assessment","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous negative result confirmed by immunofluorescence and phenotypic rescue failure; clear cell-type specificity established","pmids":["30724107"],"is_preprint":false},{"year":2019,"finding":"A missense mutation in COL4A3 (p.G856Glu) was successfully reverted toward wild type in podocyte-lineage cells isolated from patient urine using CRISPR/Cas9 genome editing (>40% reversion, <15% indels), demonstrating that podocyte-lineage cells are the relevant cellular target for COL4A3 gene correction.","method":"CRISPR/Cas9 genome editing; mCherry/GFP reporter system; Sanger sequencing in patient-derived podocyte-lineage cells","journal":"European journal of human genetics : EJHG","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct genome editing in disease-relevant cells; single lab, single method; no long-term functional rescue shown","pmids":["31754267"],"is_preprint":false},{"year":2019,"finding":"A COL4A3 frameshift mutation (c.4317delA) causing a truncated NC1 domain induces excessive endoplasmic reticulum stress and ER stress-mediated apoptosis in human podocytes. Proteasomal inhibition (MG132) increases intracellular accumulation of the truncated chain, worsening ER stress and apoptosis, identifying the proteasome as the primary degradation route for the misfolded mutant chain.","method":"Lentiviral stable transfection of human podocytes; RT-PCR; Western blot; pharmacological inhibition (MG132, brefeldin A); CRISPR/Cas9 KO podocytes","journal":"Chinese medical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in cell culture; single lab","pmids":["31306228"],"is_preprint":false},{"year":2021,"finding":"A COL4A3 variant (8-residue appendage at C-terminus of the α3 subunit of the α345 hexamer) introduced as a knock-in in mice causes GBM abnormalities and proteinuria phenocopying Alport syndrome. Crystallography and assembly studies revealed hexamer mechanisms; bioactive sites on the hexamer surface converge pathogenic pathways of Goodpasture's and Alport syndrome.","method":"Knock-in mouse model; crystallography; hexamer assembly studies; immunostaining; functional proteinuria readout","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystallography plus knock-in mouse reconstitution; multiple orthogonal methods from one study","pmids":["33774048"],"is_preprint":false},{"year":2020,"finding":"A knock-in mouse harboring Col4a3 p.Gly1332Glu recapitulates Alport syndrome features. In glomeruli, the mutant α3 chain and the normal α4/α5 chains appear to undergo proteolytic cleavage near the mutation site, producing a ~35 kDa C-terminal fragment, possibly mediated by MMP-9, while tubuli show reduced mutant collagen expression.","method":"Knock-in and compound heterozygous mouse models; Western blot; immunostaining; electron microscopy; serum urea/creatinine; MMP inhibitor inference","journal":"Matrix biology plus","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knock-in mouse with proteomic and EM readouts; MMP-9-mediated cleavage inferred from fragment size, not directly demonstrated","pmids":["33718859"],"is_preprint":false},{"year":2021,"finding":"COL4A3 expression in bronchial epithelium is negatively regulated by intronic DNA methylation (cg11797365); methylation at this site is increased by rhinovirus infection in vitro. ZNF263 binds this intronic region (by ChIP-seq), and ZNF263 silencing reduces COL4A3 expression, identifying an epigenetic/transcriptional mechanism controlling COL4A3 levels in airway epithelium.","method":"RNA-sequencing; DNA methylation bead arrays; ChIP-seq with qPCR; siRNA silencing of ZNF263","journal":"ERJ open research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq binding plus siRNA functional validation; single lab, multiple orthogonal methods","pmids":["34109240"],"is_preprint":false},{"year":2016,"finding":"ZEB1 (TCF8) binds to six of nine E2-box motifs in the COL4A3 promoter (demonstrated by EMSA) and overexpression of ZEB1 reduces COL4A3 promoter activity in luciferase reporter assays, establishing ZEB1 as a direct transcriptional repressor of COL4A3.","method":"Electrophoretic mobility shift assay (EMSA); dual-luciferase reporter assay; ZEB1 overexpression and truncation mutants","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct DNA-binding assay (EMSA) plus functional reporter assay; two orthogonal methods; consistent with earlier TCF8/PPCD finding","pmids":["27537263"],"is_preprint":false},{"year":2005,"finding":"TCF8 (ZEB1) frameshift/nonsense mutations in PPCD3 families result in ectopic expression of COL4A3 in corneal endothelial cells, demonstrated by immunohistochemistry, and a TCF8 binding site (core plus secondary) was identified in the COL4A3 promoter, establishing TCF8 as a transcriptional repressor of COL4A3 whose loss causes aberrant COL4A3 expression.","method":"Mutation analysis; in silico promoter analysis; immunohistochemistry in corneal endothelium","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — IHC of ectopic protein expression combined with promoter binding site identification; mechanistic link inferred; direct binding not shown in this paper","pmids":["16252232"],"is_preprint":false},{"year":2022,"finding":"COL4A3 missense/synonymous variants p.(Leu1598Arg) and p.(Thr255Thr) were shown by in vitro minigene assay to alter RNA splicing—p.(Leu1598Arg) eliminates an alternative full-length transcript and p.(Thr255Thr) causes in-frame deletion of exon 13—demonstrating that exonic substitutions can pathogenically disrupt COL4A3 splicing.","method":"In vitro minigene splicing assay; Sanger sequencing; clinical segregation","journal":"Frontiers in medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene functional assay directly demonstrates splicing disruption; single lab","pmids":["35386907"],"is_preprint":false},{"year":2024,"finding":"A knock-in mouse bearing Col4a3 p.Gly799R shows pathological decrease in intracellular and secreted collagen IV α3α4α5 heterotrimers; mutant α3 chains accumulate in the ER and exhibit defective secretion, causing persistent ER stress and activating the MyD88/p38 MAPK pathway. Treatment with TUDCA (ER stress inhibitor) suppresses ER stress, promotes α3 chain secretion, and improves kidney function in vivo.","method":"Transgenic knock-in mouse; Western blot; immunofluorescence; RNA-seq; in vitro cell assays; pharmacological TUDCA treatment","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in model with RNA-seq, multiple molecular readouts, and pharmacological rescue; multiple orthogonal methods in one rigorous study","pmids":["38782199"],"is_preprint":false},{"year":2023,"finding":"In podocytes and mice harboring COL4A3 p.C1616Y (murine p.C1615Y), microarray and validation experiments show upregulation of NOX4, H2O2, MMP-2, and apoptosis-related genes. NOX4 inhibition abrogates podocyte apoptosis and downregulates MMP-2 in vivo and in vitro; MMP-2 inhibition reduces apoptosis without affecting NOX4, placing COL4A3 mutation-induced podocyte apoptosis in a NOX4→MMP-2→apoptosis pathway.","method":"Microarray analysis on patient glomeruli; mutant human podocyte cell line; knock-in mice (p.C1615Y); NOX4 inhibitor (GKT137831) and MMP-2 inhibitor (SB-3CT); Western blot; immunohistochemistry; RT-PCR","journal":"Kidney international reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis by pharmacological inhibition in both in vitro and in vivo models, multiple orthogonal methods from a single rigorous study","pmids":["37705901"],"is_preprint":false},{"year":2025,"finding":"Treatment of Col4a3 p.Gly1332Glu knock-in mice with 4-phenylbutyrate (4-PBA) improves secretion of mutant α3 chains and their incorporation into extracellular matrix (likely by enhancing trimer folding), reduces GBM lesions by 54%, decreases fibrosis and glomerulosclerosis, and maintains low proteinuria. In-vitro proteasomal inhibition in cultured podocytes confirmed that misfolded mutant collagen is degraded by the proteasome.","method":"Knock-in mouse model; electron microscopy; histology; proteasome inhibitor in primary podocytes; Western blot","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 2 / Strong — in-vivo pharmacological rescue plus in-vitro mechanistic validation; multiple orthogonal readouts from one rigorous study","pmids":["40484355"],"is_preprint":false},{"year":2012,"finding":"Proteomic analysis of Col4a3-/- glomeruli revealed upregulation of vimentin (~2.5-fold by 2D-DIGE, ~5.4-fold by qRT-PCR) specifically in podocytes, as well as increased integrin α1 in mesangial cells and integrin α3 in podocytes, indicating that loss of the α3α4α5(IV) GBM network alters podocyte cytoskeletal and adhesion-receptor expression.","method":"2D-DIGE proteomics; mass spectrometry; qRT-PCR; quantitative confocal immunofluorescence; Col4a3-/- mouse model","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — discovery proteomics confirmed by independent qRT-PCR and immunofluorescence; single lab","pmids":["23236390"],"is_preprint":false}],"current_model":"COL4A3 encodes the α3 chain of type IV collagen that, together with α4 and α5 chains, assembles into the α3α4α5(IV) heterotrimer in the ER (requiring all three chains for network formation) and is secreted exclusively by podocytes into the glomerular basement membrane, where the network provides long-term filtration barrier integrity; pathogenic mutations cause defective heterotrimer assembly/secretion, ER stress with MyD88/p38 MAPK and UPR activation, proteasomal degradation of misfolded chains, and downstream podocyte apoptosis via a NOX4→MMP-2 pathway, while transcription of COL4A3 is negatively regulated by ZEB1/TCF8 binding to E2-box motifs in its promoter, and compensatory ectopic deposition of α5α6(IV) collagen can partially substitute for the absent network and delay renal failure."},"narrative":{"mechanistic_narrative":"COL4A3 encodes the α3 chain of type IV collagen, an obligate building block of the α3α4α5(IV) heterotrimeric network that constitutes the mature glomerular basement membrane (GBM) filtration barrier [PMID:8956999, PMID:14507670]. Network assembly requires all three chains: knockout of COL4A3 eliminates α3, α4, and α5(IV) from the GBM and produces progressive glomerulonephritis with GBM multilamination and end-stage renal disease, while reintroduction of human α3(IV) restores co-assembly of the heterotrimer and rescues the phenotype [PMID:8956999, PMID:14507670]. COL4A3 and the adjacent COL4A4 are arranged head-to-head and share a bidirectional, TATA-less promoter, and both chains are independently required for GBM integrity [PMID:10534397, PMID:9537506]; transcription is directly repressed by ZEB1/TCF8 binding E2-box motifs in the promoter, loss of which drives ectopic α3(IV) expression in corneal endothelium [PMID:27537263, PMID:16252232]. The chains are deposited specifically by podocytes rather than endothelial cells, identifying the podocyte lineage as the relevant target for genetic correction [PMID:30724107, PMID:31754267]. Pathogenic COL4A3 mutations—including splice-altering, frameshift, and missense changes—cause autosomal recessive and dominant Alport syndrome by disrupting heterotrimer assembly and secretion [PMID:7633417, PMID:11044206, PMID:35386907]; misfolded mutant α3 chains accumulate in the ER, are cleared by the proteasome, and trigger persistent ER stress that activates the unfolded protein response and the MyD88/p38 MAPK pathway, driving podocyte apoptosis and fibrosis [PMID:25514610, PMID:31306228, PMID:38782199]. Downstream, mutation-induced injury proceeds through a NOX4→MMP-2 apoptotic pathway in podocytes [PMID:37705901], while collagen-receptor signalling through integrin α2β1 drives fibrosis progression [PMID:24480069]. Disease severity is modulated by compensatory ectopic deposition of α5α6(IV) collagen, which partially substitutes for the absent network and prolongs renal survival [PMID:16769745]. Chemical chaperones (TUDCA, 4-PBA) that relieve ER stress and promote mutant chain secretion improve GBM lesions and kidney function, establishing the assembly/secretion defect as a tractable therapeutic target [PMID:38782199, PMID:40484355]. Absence of α3(IV) from the GBM also breaks immunological tolerance to the NC1 domain Goodpasture epitope, underlying post-transplant anti-GBM nephritis [PMID:7780062, PMID:7783419, PMID:33774048].","teleology":[{"year":1996,"claim":"Established that COL4A3 is required to assemble the α3α4α5(IV) collagen network in the GBM, defining its core in-vivo function and the basis of Alport pathology.","evidence":"COL4A3 knockout mouse analyzed by immunofluorescence, TEM, and Northern blot","pmids":["8956999"],"confidence":"High","gaps":["Did not resolve whether α3/α4/α5 are co-dependent for assembly or whether each is individually required","Cell-type source of the chains not addressed"]},{"year":1998,"claim":"Mapped the COL4A3/COL4A4 head-to-head genomic arrangement and bidirectional TATA-less promoter, defining the transcriptional architecture controlling both chains.","evidence":"Genomic cloning, RACE, and RNase protection mapping of transcription start sites","pmids":["9537506"],"confidence":"High","gaps":["No trans-acting factors identified at this stage","Tissue-specific regulation not addressed"]},{"year":1999,"claim":"Showed both α3 and α4 chains are individually required for GBM integrity and that joint loss accelerates disease, confirming non-redundant roles via the shared promoter.","evidence":"Transgenic insertional knockout (OVE250) ablating the shared promoter, with RT-PCR, immunostaining, and EM","pmids":["10534397"],"confidence":"High","gaps":["Insertional deletion removes regulatory elements as well as coding exons, complicating attribution"]},{"year":2003,"claim":"Demonstrated by transgenic rescue that providing α3(IV) restores heterotrimer co-assembly and reverses the Alport phenotype, proving defective assembly is the pathogenic mechanism.","evidence":"YAC transgenic rescue in Col4a3-/- mice with immunofluorescence and functional renal readouts","pmids":["14507670"],"confidence":"High","gaps":["Did not define cell-type of expression required for rescue","Did not address mutant (vs absent) chain behavior"]},{"year":2006,"claim":"Identified compensatory α5α6(IV) deposition as a strain-dependent modifier that partially substitutes for the lost network and prolongs survival, explaining phenotypic variability.","evidence":"Col4a3-/- mice across genetic backgrounds with immunofluorescence and survival analysis","pmids":["16769745"],"confidence":"High","gaps":["Molecular trigger for the isoform switch unknown","Human relevance of α5α6 substitution not established here"]},{"year":2005,"claim":"Linked ZEB1/TCF8 to COL4A3 transcriptional repression, showing that loss of the repressor causes ectopic COL4A3 expression in corneal endothelium (PPCD3).","evidence":"TCF8 mutation analysis, promoter binding-site identification, and IHC of corneal endothelium","pmids":["16252232"],"confidence":"Medium","gaps":["Direct DNA binding not demonstrated in this study","Mechanism inferred from IHC and in silico analysis"]},{"year":2016,"claim":"Confirmed ZEB1 as a direct transcriptional repressor of COL4A3 by showing binding to E2-box motifs and repression of promoter activity.","evidence":"EMSA and dual-luciferase reporter assays with ZEB1 overexpression and truncation mutants","pmids":["27537263"],"confidence":"High","gaps":["In-vivo relevance to GBM regulation not tested","Other E2-box factors not excluded"]},{"year":2021,"claim":"Extended transcriptional control of COL4A3 to an epigenetic mechanism in airway epithelium, identifying intronic methylation and ZNF263 binding as regulators of expression.","evidence":"RNA-seq, methylation arrays, ChIP-seq, and ZNF263 siRNA silencing in bronchial epithelium","pmids":["34109240"],"confidence":"Medium","gaps":["Relevance to renal/GBM COL4A3 expression unclear","Single-lab finding in non-renal tissue"]},{"year":2014,"claim":"Placed integrin α2β1 collagen-receptor signalling as a driver of fibrosis progression downstream of GBM injury, identifying a modifiable disease pathway.","evidence":"Col4a3-/-/Itga2-/- double-knockout mice with EM, MMP/TIMP profiling, and survival readouts","pmids":["24480069"],"confidence":"High","gaps":["Cell-type mediating integrin signalling not isolated","Mechanism connecting integrin to MMP normalization not fully resolved"]},{"year":2014,"claim":"Began defining how mutant α3 chains cause injury, showing intracellular retention and differential UPR activation in podocytes.","evidence":"Transfection of podocytes with mutant COL4A3 and UPR pathway analysis","pmids":["25514610"],"confidence":"Medium","gaps":["Single method type in cell culture","Causal link from UPR to phenotype severity not demonstrated in vivo"]},{"year":2019,"claim":"Established the podocyte lineage as the obligate source of α3(IV) and the relevant target for gene correction, while excluding endothelial cells.","evidence":"Endothelial-specific transgene failure to rescue Col4a3-/- mice; CRISPR/Cas9 reversion in patient urine-derived podocyte-lineage cells","pmids":["30724107","31754267"],"confidence":"High","gaps":["Long-term functional rescue after CRISPR correction not shown","Editing efficiency in vivo not established"]},{"year":2019,"claim":"Identified the proteasome as the degradation route for misfolded mutant α3 chains and linked their accumulation to ER stress-mediated podocyte apoptosis.","evidence":"Lentiviral expression of truncated COL4A3 in human podocytes with MG132/brefeldin A inhibition and CRISPR KO","pmids":["31306228"],"confidence":"Medium","gaps":["Single-lab cell-culture system","Specific ER stress effectors not delineated"]},{"year":2020,"claim":"Showed in a knock-in model that mutant and partner chains undergo proteolytic cleavage producing a C-terminal fragment, implicating extracellular processing in pathology.","evidence":"Col4a3 p.Gly1332Glu knock-in mice with Western blot, immunostaining, EM, and MMP-inhibitor inference","pmids":["33718859"],"confidence":"Medium","gaps":["MMP-9 mediation inferred from fragment size, not directly demonstrated","Functional consequence of the fragment unknown"]},{"year":2021,"claim":"Resolved hexamer assembly mechanisms structurally and showed bioactive NC1 surface sites converge the pathogenic pathways of Goodpasture's and Alport syndromes.","evidence":"Knock-in mouse with C-terminal appendage, crystallography, and hexamer assembly studies","pmids":["33774048"],"confidence":"High","gaps":["Direct demonstration of autoantibody-triggering in vivo not part of this study"]},{"year":2023,"claim":"Defined a NOX4→MMP-2→apoptosis pathway as the downstream effector of COL4A3 mutation-induced podocyte injury, identifying druggable nodes.","evidence":"Mutant human podocytes and p.C1615Y knock-in mice with NOX4 and MMP-2 inhibitors, microarray, and IHC","pmids":["37705901"],"confidence":"High","gaps":["Connection between ER stress and NOX4 induction not fully mapped","Generalizability across mutation classes not established"]},{"year":2024,"claim":"Linked the secretion defect to a defined ER-stress signalling axis (MyD88/p38 MAPK) and demonstrated pharmacological rescue, establishing ER stress as a therapeutic target.","evidence":"Col4a3 p.Gly799R knock-in mice with RNA-seq, Western blot, immunofluorescence, and TUDCA treatment","pmids":["38782199"],"confidence":"High","gaps":["Whether all mutation classes respond to ER-stress relief unclear","Durability of TUDCA benefit not addressed"]},{"year":2025,"claim":"Confirmed that chemical-chaperone rescue (4-PBA) enhances mutant chain folding, secretion, and ECM incorporation, reducing GBM lesions and fibrosis.","evidence":"Col4a3 p.Gly1332Glu knock-in mice with EM, histology, and proteasome-inhibition validation in primary podocytes","pmids":["40484355"],"confidence":"High","gaps":["Mutation-class dependence of response not defined","Translational dosing/safety not addressed"]},{"year":null,"claim":"How upstream ER stress signalling connects to the NOX4→MMP-2 apoptotic axis and to integrin-driven fibrosis, and which mutation classes are amenable to chaperone-based correction, remains to be unified.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No single model integrates ER stress, oxidative/MMP, and integrin pathways","Predictors of therapeutic responsiveness across mutation types not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,3,14]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[0,3,4]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[10,13,20]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,22]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,3,9]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[10,13,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,6,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[17,18]}],"complexes":["α3α4α5(IV) collagen heterotrimer","α345(IV) NC1 hexamer"],"partners":["COL4A4","COL4A5","ITGA2","DDR1","ZEB1","ZNF263"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q01955","full_name":"Collagen alpha-3(IV) chain","aliases":["Goodpasture antigen"],"length_aa":1670,"mass_kda":161.8,"function":"Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen Tumstatin, a cleavage fragment corresponding to the collagen alpha 3(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity; these two anti-tumor properties may be regulated via RGD-independent ITGB3-mediated mechanisms","subcellular_location":"Secreted, extracellular space, extracellular matrix, basement membrane","url":"https://www.uniprot.org/uniprotkb/Q01955/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/COL4A3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/COL4A3","total_profiled":1310},"omim":[{"mim_id":"621004","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 4; ADMIO4","url":"https://www.omim.org/entry/621004"},{"mim_id":"620536","title":"ALPORT SYNDROME 3B, AUTOSOMAL RECESSIVE; ATS3B","url":"https://www.omim.org/entry/620536"},{"mim_id":"620320","title":"HEMATURIA, BENIGN FAMILIAL, 2; BFH2","url":"https://www.omim.org/entry/620320"},{"mim_id":"613420","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 1; KCTD1","url":"https://www.omim.org/entry/613420"},{"mim_id":"611499","title":"BETA-GLUCURONIDASE; GUSB","url":"https://www.omim.org/entry/611499"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Endoplasmic reticulum","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"retina","ntpm":33.6}],"url":"https://www.proteinatlas.org/search/COL4A3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q01955","domains":[{"cath_id":"2.170.240.10","chopping":"1447-1502_1511-1529_1536-1668","consensus_level":"medium","plddt":95.1848,"start":1447,"end":1668}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01955","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01955-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01955-F1-predicted_aligned_error_v6.png","plddt_mean":47.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COL4A3","jax_strain_url":"https://www.jax.org/strain/search?query=COL4A3"},"sequence":{"accession":"Q01955","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01955.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01955/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01955"}},"corpus_meta":[{"pmid":"8956999","id":"PMC_8956999","title":"Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.","date":"1996","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8956999","citation_count":298,"is_preprint":false},{"pmid":"7987301","id":"PMC_7987301","title":"Mutations in the type IV collagen alpha 3 (COL4A3) gene in autosomal recessive Alport syndrome.","date":"1994","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7987301","citation_count":186,"is_preprint":false},{"pmid":"12028435","id":"PMC_12028435","title":"COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12028435","citation_count":167,"is_preprint":false},{"pmid":"16252232","id":"PMC_16252232","title":"Mutations in TCF8 cause posterior polymorphous corneal dystrophy and ectopic expression of COL4A3 by corneal endothelial cells.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16252232","citation_count":154,"is_preprint":false},{"pmid":"11134255","id":"PMC_11134255","title":"Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome.","date":"2001","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/11134255","citation_count":150,"is_preprint":false},{"pmid":"24052634","id":"PMC_24052634","title":"COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome.","date":"2013","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/24052634","citation_count":134,"is_preprint":false},{"pmid":"19357112","id":"PMC_19357112","title":"Clinico-pathological correlations in 127 patients in 11 large pedigrees, segregating one of three heterozygous mutations in the COL4A3/ COL4A4 genes associated with familial haematuria and significant late progression to proteinuria and chronic kidney disease from focal segmental glomerulosclerosis.","date":"2009","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/19357112","citation_count":124,"is_preprint":false},{"pmid":"15086897","id":"PMC_15086897","title":"Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene.","date":"2004","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/15086897","citation_count":112,"is_preprint":false},{"pmid":"11044206","id":"PMC_11044206","title":"Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation.","date":"2000","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11044206","citation_count":109,"is_preprint":false},{"pmid":"9269635","id":"PMC_9269635","title":"Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes (COL4A3 and COL4A4).","date":"1997","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/9269635","citation_count":106,"is_preprint":false},{"pmid":"7633417","id":"PMC_7633417","title":"Splice-mediated insertion of an Alu sequence in the COL4A3 mRNA causing autosomal recessive Alport syndrome.","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7633417","citation_count":98,"is_preprint":false},{"pmid":"11961012","id":"PMC_11961012","title":"Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria.","date":"2002","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/11961012","citation_count":86,"is_preprint":false},{"pmid":"33391746","id":"PMC_33391746","title":"Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review.","date":"2020","source":"Clinical kidney journal","url":"https://pubmed.ncbi.nlm.nih.gov/33391746","citation_count":76,"is_preprint":false},{"pmid":"20029656","id":"PMC_20029656","title":"Polymorphisms in COL4A3 and COL4A4 genes associated with keratoconus.","date":"2009","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/20029656","citation_count":66,"is_preprint":false},{"pmid":"17396119","id":"PMC_17396119","title":"Sixteen novel mutations identified in COL4A3, COL4A4, and COL4A5 genes in Slovenian families with Alport syndrome and benign familial hematuria.","date":"2007","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/17396119","citation_count":58,"is_preprint":false},{"pmid":"24480069","id":"PMC_24480069","title":"Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice.","date":"2014","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24480069","citation_count":57,"is_preprint":false},{"pmid":"14871398","id":"PMC_14871398","title":"COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN).","date":"2004","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/14871398","citation_count":55,"is_preprint":false},{"pmid":"25514610","id":"PMC_25514610","title":"Frequency of COL4A3/COL4A4 mutations amongst families segregating glomerular microscopic hematuria and evidence for activation of the unfolded protein response. Focal and segmental glomerulosclerosis is a frequent development during ageing.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25514610","citation_count":55,"is_preprint":false},{"pmid":"16769745","id":"PMC_16769745","title":"Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice.","date":"2006","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/16769745","citation_count":55,"is_preprint":false},{"pmid":"10534397","id":"PMC_10534397","title":"Insertional mutation of the collagen genes Col4a3 and Col4a4 in a mouse model of Alport syndrome.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10534397","citation_count":54,"is_preprint":false},{"pmid":"25596306","id":"PMC_25596306","title":"COL4A3 mutations cause focal segmental glomerulosclerosis.","date":"2014","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25596306","citation_count":54,"is_preprint":false},{"pmid":"37428955","id":"PMC_37428955","title":"Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.","date":"2023","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/37428955","citation_count":51,"is_preprint":false},{"pmid":"35602506","id":"PMC_35602506","title":"Genotype-Phenotype Correlations for Pathogenic COL4A3-COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35602506","citation_count":46,"is_preprint":false},{"pmid":"15954103","id":"PMC_15954103","title":"Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndrome.","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15954103","citation_count":42,"is_preprint":false},{"pmid":"31754267","id":"PMC_31754267","title":"New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells.","date":"2019","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/31754267","citation_count":41,"is_preprint":false},{"pmid":"14507670","id":"PMC_14507670","title":"A human-mouse chimera of the alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- Alport mice.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14507670","citation_count":40,"is_preprint":false},{"pmid":"7780062","id":"PMC_7780062","title":"Autosomal recessive Alport syndrome: mutation in the COL4A3 gene in a woman with Alport syndrome and posttransplant antiglomerular basement membrane nephritis.","date":"1995","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/7780062","citation_count":39,"is_preprint":false},{"pmid":"9537506","id":"PMC_9537506","title":"Two genes, COL4A3 and COL4A4 coding for the human alpha3(IV) and alpha4(IV) collagen chains are arranged head-to-head on chromosome 2q36.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9537506","citation_count":38,"is_preprint":false},{"pmid":"16775036","id":"PMC_16775036","title":"Chronic renal failure and shortened lifespan in COL4A3+/- mice: an animal model for thin basement membrane nephropathy.","date":"2006","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/16775036","citation_count":34,"is_preprint":false},{"pmid":"37849993","id":"PMC_37849993","title":"The Phenotypic Spectrum of COL4A3 Heterozygotes.","date":"2023","source":"Kidney international reports","url":"https://pubmed.ncbi.nlm.nih.gov/37849993","citation_count":31,"is_preprint":false},{"pmid":"30968591","id":"PMC_30968591","title":"Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30968591","citation_count":30,"is_preprint":false},{"pmid":"17216251","id":"PMC_17216251","title":"Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseases.","date":"2007","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17216251","citation_count":28,"is_preprint":false},{"pmid":"18661361","id":"PMC_18661361","title":"COL4A3/COL4A4 mutations link familial hematuria and focal segmental glomerulosclerosis. glomerular epithelium destruction via basement membrane thinning?","date":"2008","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/18661361","citation_count":28,"is_preprint":false},{"pmid":"7783419","id":"PMC_7783419","title":"A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome.","date":"1995","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/7783419","citation_count":26,"is_preprint":false},{"pmid":"33774048","id":"PMC_33774048","title":"Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture's and Alport diseases.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33774048","citation_count":25,"is_preprint":false},{"pmid":"24198271","id":"PMC_24198271","title":"Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.","date":"2013","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/24198271","citation_count":25,"is_preprint":false},{"pmid":"18439107","id":"PMC_18439107","title":"COL4A3 founder mutations in Greek-Cypriot families with thin basement membrane nephropathy and focal segmental glomerulosclerosis dating from around 18th century.","date":"2008","source":"Genetic testing","url":"https://pubmed.ncbi.nlm.nih.gov/18439107","citation_count":24,"is_preprint":false},{"pmid":"25381091","id":"PMC_25381091","title":"Whole exome sequencing reveals novel COL4A3 and COL4A4 mutations and resolves diagnosis in Chinese families with kidney disease.","date":"2014","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/25381091","citation_count":23,"is_preprint":false},{"pmid":"30012629","id":"PMC_30012629","title":"COL4A3 Gene Variants and Diabetic Kidney Disease in MODY.","date":"2018","source":"Clinical journal of the American Society of Nephrology : CJASN","url":"https://pubmed.ncbi.nlm.nih.gov/30012629","citation_count":22,"is_preprint":false},{"pmid":"28451395","id":"PMC_28451395","title":"Association of COL4A3 (rs55703767), MMP-9 (rs17576)and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes.","date":"2017","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/28451395","citation_count":22,"is_preprint":false},{"pmid":"25083577","id":"PMC_25083577","title":"Polymorphism analysis of COL4A3 and COL4A4 genes in Greek patients with keratoconus.","date":"2014","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25083577","citation_count":22,"is_preprint":false},{"pmid":"38782199","id":"PMC_38782199","title":"Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation.","date":"2024","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/38782199","citation_count":20,"is_preprint":false},{"pmid":"28197741","id":"PMC_28197741","title":"Correlation between the COL4A3, MMP-9, and TIMP-1 polymorphisms and risk of keratoconus.","date":"2017","source":"Japanese journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/28197741","citation_count":20,"is_preprint":false},{"pmid":"28542346","id":"PMC_28542346","title":"Novel mutations in COL4A3, COL4A4, and COL4A5 in Chinese patients with Alport Syndrome.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28542346","citation_count":20,"is_preprint":false},{"pmid":"25307543","id":"PMC_25307543","title":"Collagen type IV-related nephropathies in Portugal: pathogenic COL4A3 and COL4A4 mutations and clinical characterization of 25 families.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25307543","citation_count":19,"is_preprint":false},{"pmid":"30883042","id":"PMC_30883042","title":"Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30883042","citation_count":19,"is_preprint":false},{"pmid":"30724107","id":"PMC_30724107","title":"Endothelial cell-specific collagen type IV-α3 expression does not rescue Alport syndrome in Col4a3-/- mice.","date":"2019","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30724107","citation_count":18,"is_preprint":false},{"pmid":"34326188","id":"PMC_34326188","title":"COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.","date":"2021","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/34326188","citation_count":18,"is_preprint":false},{"pmid":"23236390","id":"PMC_23236390","title":"Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23236390","citation_count":17,"is_preprint":false},{"pmid":"30053909","id":"PMC_30053909","title":"Associations of high-altitude polycythemia with polymorphisms in PIK3CD and COL4A3 in Tibetan populations.","date":"2018","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/30053909","citation_count":17,"is_preprint":false},{"pmid":"12381925","id":"PMC_12381925","title":"Segregation of experimental autoimmune glomerulonephritis as a complex genetic trait and exclusion of Col4a3 as a candidate gene.","date":"2002","source":"Experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/12381925","citation_count":16,"is_preprint":false},{"pmid":"35386907","id":"PMC_35386907","title":"Presumed COL4A3/COL4A4 Missense/Synonymous Variants Induce Aberrant Splicing.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35386907","citation_count":15,"is_preprint":false},{"pmid":"23927549","id":"PMC_23927549","title":"A founder mutation in COL4A3 causes autosomal recessive Alport syndrome in the Ashkenazi Jewish population.","date":"2013","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23927549","citation_count":15,"is_preprint":false},{"pmid":"31306228","id":"PMC_31306228","title":"Endoplasmic reticulum stress and proteasome pathway involvement in human podocyte injury with a truncated COL4A3 mutation.","date":"2019","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31306228","citation_count":13,"is_preprint":false},{"pmid":"20177710","id":"PMC_20177710","title":"Novel heterozygous COL4A3 mutation in a family with late-onset ESRD.","date":"2010","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/20177710","citation_count":13,"is_preprint":false},{"pmid":"32232700","id":"PMC_32232700","title":"How to resolve confusion in the clinical setting for the diagnosis of heterozygous COL4A3 or COL4A4 gene variants? Discussion and suggestions from nephrologists.","date":"2020","source":"Clinical and experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/32232700","citation_count":12,"is_preprint":false},{"pmid":"38317457","id":"PMC_38317457","title":"Increased prevalence of kidney cysts in individuals carrying heterozygous COL4A3 or COL4A4 pathogenic variants.","date":"2024","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/38317457","citation_count":12,"is_preprint":false},{"pmid":"17726307","id":"PMC_17726307","title":"A novel mutation of COL4A3 presents a different contribution to Alport syndrome and thin basement membrane nephropathy.","date":"2007","source":"American journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/17726307","citation_count":12,"is_preprint":false},{"pmid":"33613712","id":"PMC_33613712","title":"Differential expression of COL4A3 and collagen in upward and downward progressing types of nasopharyngeal carcinoma.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33613712","citation_count":11,"is_preprint":false},{"pmid":"25450602","id":"PMC_25450602","title":"A new mutation in the COL4A3 gene responsible for autosomal dominant Alport syndrome, which only generates hearing loss in some carriers.","date":"2014","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25450602","citation_count":11,"is_preprint":false},{"pmid":"23297803","id":"PMC_23297803","title":"A novel COL4A3 mutation causes autosomal-recessive Alport syndrome in a large Turkish family.","date":"2013","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/23297803","citation_count":10,"is_preprint":false},{"pmid":"15199166","id":"PMC_15199166","title":"Patients with Goodpasture's disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen alpha 3 chain.","date":"2004","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/15199166","citation_count":10,"is_preprint":false},{"pmid":"33718859","id":"PMC_33718859","title":"A glycine substitution in the collagenous domain of Col4a3 in mice recapitulates late onset Alport syndrome.","date":"2020","source":"Matrix biology plus","url":"https://pubmed.ncbi.nlm.nih.gov/33718859","citation_count":10,"is_preprint":false},{"pmid":"18436078","id":"PMC_18436078","title":"Novel COL4A3 mutations in African American siblings with autosomal recessive Alport syndrome.","date":"2008","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/18436078","citation_count":10,"is_preprint":false},{"pmid":"37705901","id":"PMC_37705901","title":"COL4A3 Mutation Induced Podocyte Apoptosis by Dysregulation of NADPH Oxidase 4 and MMP-2.","date":"2023","source":"Kidney international reports","url":"https://pubmed.ncbi.nlm.nih.gov/37705901","citation_count":9,"is_preprint":false},{"pmid":"35743114","id":"PMC_35743114","title":"Col4a3 Mice on Balb/C Background Have Less Severe Cardiorespiratory Phenotype and SGLT2 Over-Expression Compared to 129x1/SvJ and C57Bl/6 Backgrounds.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35743114","citation_count":9,"is_preprint":false},{"pmid":"35090027","id":"PMC_35090027","title":"Heterozygous COL4A3/COL4A4 mutations: the hidden part of the iceberg?","date":"2022","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/35090027","citation_count":9,"is_preprint":false},{"pmid":"34109240","id":"PMC_34109240","title":"COL4A3 expression in asthmatic epithelium depends on intronic methylation and ZNF263 binding.","date":"2021","source":"ERJ open research","url":"https://pubmed.ncbi.nlm.nih.gov/34109240","citation_count":8,"is_preprint":false},{"pmid":"37441478","id":"PMC_37441478","title":"Abnormal mRNA Splicing Effect of COL4A3 to COL4A5 Unclassified Variants.","date":"2023","source":"Kidney international reports","url":"https://pubmed.ncbi.nlm.nih.gov/37441478","citation_count":8,"is_preprint":false},{"pmid":"38357258","id":"PMC_38357258","title":"A Deeper Insight into COL4A3, COL4A4, and COL4A5 Variants and Genotype-Phenotype Correlation of a Turkish Cohort with Alport Syndrome.","date":"2023","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/38357258","citation_count":8,"is_preprint":false},{"pmid":"29089023","id":"PMC_29089023","title":"Phenotype variability in a large Spanish family with Alport syndrome associated with novel mutations in COL4A3 gene.","date":"2017","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/29089023","citation_count":8,"is_preprint":false},{"pmid":"35301649","id":"PMC_35301649","title":"Genetic heterogeneity in GJB2, COL4A3, ATP6V1B1 and EDNRB variants detected among hearing impaired families in Morocco.","date":"2022","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35301649","citation_count":7,"is_preprint":false},{"pmid":"28674241","id":"PMC_28674241","title":"Mutation analysis of COL4A3 and COL4A4 genes in a Chinese autosomal-dominant Alport syndrome family.","date":"2017","source":"Journal of genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28674241","citation_count":6,"is_preprint":false},{"pmid":"40484355","id":"PMC_40484355","title":"Chemical chaperone 4-phenylbutyrate treatment alleviates the kidney phenotype in a mouse model of Alport syndrome with a pathogenic variant in Col4a3.","date":"2025","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/40484355","citation_count":6,"is_preprint":false},{"pmid":"30661074","id":"PMC_30661074","title":"Possible Digenic Disease in a Caucasian Family with COL4A3 and COL4A5 Mutations.","date":"2019","source":"Nephron","url":"https://pubmed.ncbi.nlm.nih.gov/30661074","citation_count":6,"is_preprint":false},{"pmid":"39424670","id":"PMC_39424670","title":"Slowly progressive autosomal dominant Alport Syndrome due to COL4A3 splicing variant.","date":"2024","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/39424670","citation_count":6,"is_preprint":false},{"pmid":"35369551","id":"PMC_35369551","title":"Heterozygous Urinary Abnormality-Causing Variants of COL4A3 and COL4A4 Affect Severity of Autosomal Recessive Alport Syndrome.","date":"2020","source":"Kidney360","url":"https://pubmed.ncbi.nlm.nih.gov/35369551","citation_count":5,"is_preprint":false},{"pmid":"38978054","id":"PMC_38978054","title":"Four novel mutations identified in the COL4A3, COL4A4 and COL4A5 genes in 10 families with Alport syndrome.","date":"2024","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38978054","citation_count":5,"is_preprint":false},{"pmid":"33079919","id":"PMC_33079919","title":"Association of Collagen Gene (COL4A3) rs55703767 Variant With Response to Riboflavin/Ultraviolet A-Induced Collagen Cross-Linking in Female Patients With Keratoconus.","date":"2021","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/33079919","citation_count":5,"is_preprint":false},{"pmid":"27537263","id":"PMC_27537263","title":"Investigating the Molecular Basis of PPCD3: Characterization of ZEB1 Regulation of COL4A3 Expression.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/27537263","citation_count":5,"is_preprint":false},{"pmid":"33524082","id":"PMC_33524082","title":"Compound Mutations of the COL4A3 including a Novel Allele Identified in a Patient with Alport Syndrome.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/33524082","citation_count":5,"is_preprint":false},{"pmid":"39042048","id":"PMC_39042048","title":"Characterization of Ocular Morphology in Col4a3-/- Mice as a Murine Model for Alport Syndrome.","date":"2024","source":"Translational vision science & technology","url":"https://pubmed.ncbi.nlm.nih.gov/39042048","citation_count":4,"is_preprint":false},{"pmid":"33550735","id":"PMC_33550735","title":"COL1A1, COL4A3, TIMP2 and TGFB1 polymorphisms in cervical insufficiency.","date":"2021","source":"Journal of perinatal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33550735","citation_count":4,"is_preprint":false},{"pmid":"32743880","id":"PMC_32743880","title":"Alport syndrome: Proteomic analysis identifies early molecular pathway alterations in Col4a3 knock out mice.","date":"2020","source":"Nephrology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/32743880","citation_count":4,"is_preprint":false},{"pmid":"33305316","id":"PMC_33305316","title":"NPHS2 gene polymorphism aggravates renal damage caused by focal segmental glomerulosclerosis with COL4A3 mutation.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/33305316","citation_count":3,"is_preprint":false},{"pmid":"38911338","id":"PMC_38911338","title":"Integrated Analysis Reveals COL4A3 as a Novel Diagnostic and Therapeutic Target in UV-Related Skin Cutaneous Melanoma.","date":"2024","source":"Clinical, cosmetic and investigational dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/38911338","citation_count":3,"is_preprint":false},{"pmid":"30881523","id":"PMC_30881523","title":"A Novel Heterozygous Mutation of the COL4A3 Gene Causes a Peculiar Phenotype without Hematuria and Renal Function Impairment in a Chinese Family.","date":"2019","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/30881523","citation_count":3,"is_preprint":false},{"pmid":"32332277","id":"PMC_32332277","title":"Thrombosis risk of Alport syndrome patients: evaluation of cardiological, clinical, biochemical, genetic and possible causes of inherited thrombophilia and identification of a novel COL4A3 variant.","date":"2020","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/32332277","citation_count":3,"is_preprint":false},{"pmid":"29742505","id":"PMC_29742505","title":"The COL4A3 and COL4A4 Digenic Mutations in cis Result in Benign Familial Hematuria in a Large Chinese Family.","date":"2018","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/29742505","citation_count":3,"is_preprint":false},{"pmid":"31925849","id":"PMC_31925849","title":"Successful renal transplantation in a family with a novel mutation in COL4A3 gene and autosomal recessive Alport syndrome.","date":"2020","source":"Nephrology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/31925849","citation_count":3,"is_preprint":false},{"pmid":"34888854","id":"PMC_34888854","title":"Pseudodominant Alport syndrome caused by pathogenic homozygous and compound heterozygous COL4A3 splicing variants.","date":"2021","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34888854","citation_count":2,"is_preprint":false},{"pmid":"40866801","id":"PMC_40866801","title":"Pathogenic synonymous variation of the COL4A3 gene causing Alport syndrome comorbid with IgA deposition in a toddler: a case report.","date":"2025","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/40866801","citation_count":2,"is_preprint":false},{"pmid":"25525413","id":"PMC_25525413","title":"Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient mice.","date":"2014","source":"Proteome science","url":"https://pubmed.ncbi.nlm.nih.gov/25525413","citation_count":2,"is_preprint":false},{"pmid":"39071776","id":"PMC_39071776","title":"Case report: A novel compound heterozygous variant in the COL4A3 gene was identified in a patient with autosomal recessive Alport syndrome.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39071776","citation_count":2,"is_preprint":false},{"pmid":"16014809","id":"PMC_16014809","title":"Evaluation of canine COL4A3 and COL4A4 as candidates for familial renal disease in the Norwegian elkhound.","date":"2005","source":"The Journal of heredity","url":"https://pubmed.ncbi.nlm.nih.gov/16014809","citation_count":2,"is_preprint":false},{"pmid":"28856578","id":"PMC_28856578","title":"A case of mild phenotype Alport syndrome caused by COL4A3 mutations.","date":"2017","source":"CEN case reports","url":"https://pubmed.ncbi.nlm.nih.gov/28856578","citation_count":2,"is_preprint":false},{"pmid":"28509228","id":"PMC_28509228","title":"Renal transplantations from parents to siblings with autosomal recessive Alport syndrome caused by a rearrangement in an intronic antisense Alu element in the COL4A3 gene led to different outcomes.","date":"2012","source":"CEN case reports","url":"https://pubmed.ncbi.nlm.nih.gov/28509228","citation_count":2,"is_preprint":false},{"pmid":"39924725","id":"PMC_39924725","title":"Effects of a Novel COL4A3 Homozygous/Heterozygous Splicing Mutation on the Mild Phenotype in a Family With Autosomal Recessive Alport Syndrome and a Literature Review.","date":"2025","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39924725","citation_count":1,"is_preprint":false},{"pmid":"40806767","id":"PMC_40806767","title":"Lithuanian Study on COL4A3 and COL4A4 Genetic Variants in Alport Syndrome: Clinical Characterization of 52 Individuals from 38 Families.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40806767","citation_count":1,"is_preprint":false},{"pmid":"40169949","id":"PMC_40169949","title":"Whole exome sequencing shows novel COL4A3 and COL4A4 variants as causes of Alport syndrome in Rio Grande do Norte, Brazil.","date":"2025","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40169949","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54782,"output_tokens":6233,"usd":0.12892,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15070,"output_tokens":5178,"usd":0.1024,"stage2_stop_reason":"end_turn"},"total_usd":0.23132,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Knockout of COL4A3 in mice results in absence of the α3, α4, and α5(IV) collagen chains from the glomerular basement membrane (GBM), with persistence of α1 and α2 chains, demonstrating that COL4A3 is required for assembly of the α3α4α5(IV) network in the GBM. Loss causes progressive glomerulonephritis with GBM multilamination, fibronectin/HSPG/laminin-1/entactin accumulation, and end-stage renal disease.\",\n      \"method\": \"COL4A3 knockout mouse; immunofluorescence; transmission electron microscopy; Northern blot\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with multiple orthogonal methods (IF, TEM, Northern blot), replicated across subsequent studies\",\n      \"pmids\": [\"8956999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Deletion of exons 1–12 of Col4a4 together with exons 1–2 of the adjacent Col4a3 and the intergenic promoter abolishes transcription and protein expression of both chains, confirming that the two genes share a bidirectional promoter and that both α3 and α4 chains are individually required for GBM integrity; loss of both accelerates disease onset compared with loss of α3 alone.\",\n      \"method\": \"Transgenic insertional knockout (OVE250 line); FISH mapping; RT-PCR; immunostaining; electron microscopy\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ablation confirmed by molecular and histological methods; compared to single-gene KO\",\n      \"pmids\": [\"10534397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"COL4A3 and COL4A4 are arranged head-to-head on chromosome 2q36, sharing a bidirectional promoter region enriched in CpG dinucleotides, GC boxes, CTC boxes, and a CCAAT box but lacking a TATA box; transcription start sites for each gene were mapped by RACE and RNase protection assays.\",\n      \"method\": \"Genomic cloning; RACE; RNase protection assay; nucleotide sequence analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct experimental mapping of transcription start sites and promoter architecture, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"9537506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Expression of human COL4A3 (via YAC transgene) in Col4a3-/- mice restores co-assembly of the α3/α4/α5(IV) heterotrimer specifically at sites of human α3(IV) expression, rescues GBM function, and reverses the Alport phenotype. This demonstrates that expression of all three chains is required for network assembly and that defective assembly is the pathogenic mechanism.\",\n      \"method\": \"YAC transgenic rescue in Col4a3-/- mice; immunofluorescence; histology; functional renal assessment\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in-vivo reconstitution with human transgene rescuing KO phenotype, multiple orthogonal readouts\",\n      \"pmids\": [\"14507670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In Col4a3-/- mice, loss of the α3/α4(IV) chains from the GBM induces ectopic deposition of α5/α6(IV) collagen; the degree of this compensatory isoform switch is strain-dependent (abundant in C57BL/6, near-absent in 129X1/Sv) and correlates with ~46% longer renal survival, revealing a functional substitution capacity of α5α6(IV) for the absent α3α4α5(IV) network.\",\n      \"method\": \"Col4a3-/- mouse on multiple genetic backgrounds; immunofluorescence; survival analysis; X-linked inheritance analysis in F1 crosses\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mouse strains, genetic crosses, immunohistochemistry, replicated functional outcome\",\n      \"pmids\": [\"16769745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A G-to-T transversion in COL4A3 intron V activates a cryptic splice acceptor within an antisense Alu element, causing insertion of a 74-bp Alu-derived sequence into the COL4A3 mRNA, disrupting the open reading frame and causing autosomal recessive Alport syndrome.\",\n      \"method\": \"mRNA screening; RT-PCR; direct sequencing; family segregation analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA-level confirmation of splice-mediated Alu insertion with family segregation; mechanistically defined\",\n      \"pmids\": [\"7633417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A COL4A3 splice site mutation causing skipping of exon 21 (in-frame deletion, NC domain intact) produces a COL4A3 chain predicted to be incorporated into the triple helix and exert a dominant-negative effect, establishing the molecular basis for autosomal dominant Alport syndrome.\",\n      \"method\": \"Nested RT-PCR; DHPLC; DNA sequencing; family segregation\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, mRNA-level confirmation of exon skipping; dominant-negative mechanism inferred from structural prediction, not reconstituted in vitro\",\n      \"pmids\": [\"11044206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A 7-bp deletion in exon 5 of COL4A3 predicts truncation of the α3(IV) chain with loss of 222 amino acids from the carboxy-terminal NC1 domain; the truncated chain is predicted unable to form trimers, and the loss of the Goodpasture epitope (residing in the NC1 domain) is proposed to underlie post-transplant anti-GBM nephritis.\",\n      \"method\": \"PCR amplification and sequencing of COL4A3 exon 5; parental heterozygosity confirmed by sequencing\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — sequence-based mechanism inference confirmed by family analysis; trimer-assembly failure and epitope loss are inferred, not biochemically reconstituted\",\n      \"pmids\": [\"7780062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Post-transplant alloantibodies in an autosomal recessive Alport patient with a COL4A3 mutation (predicted loss of 85% of the α3(IV) NC1 domain) target primarily the α3(IV) collagen chain, the same epitope targeted in X-linked Alport patients with COL4A5 deletions, demonstrating that absence of α3(IV) from the GBM (whether from failed synthesis or failed assembly) leads to loss of immunological tolerance to the α3(IV) NC1 domain.\",\n      \"method\": \"Recombinant type IV collagen domain binding assays; characterization of alloantibody specificity using GBM constituents\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — recombinant domain binding assay identifying alloantibody target; single lab, two orthogonal methods\",\n      \"pmids\": [\"7783419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Collagen receptors DDR1 and integrin α2β1 regulate maturation of the GBM. In the Col4a3-/- Alport model, loss of integrin α2β1 (COL4A3-/-/ITGA2-/- double KO) reduces proteinuria, lowers blood urea nitrogen, extends lifespan by ~20%, decreases glomerular and tubulointerstitial matrix deposition, and normalises elevated MMP2/9/12 and TIMP1 levels, demonstrating that integrin α2β1-mediated collagen signalling drives fibrosis progression.\",\n      \"method\": \"Double-knockout mouse model; electron microscopy; MMP/TIMP expression analysis; survival and functional readouts\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in double-KO mice with multiple functional and molecular readouts; mechanistic pathway placement\",\n      \"pmids\": [\"24480069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In cultured podocytes transfected with mutant COL4A3 chains, mutant collagens are retained intracellularly and differentially activate the unfolded protein response (UPR) cascade, implicating ER stress as a modulator of phenotypic severity in COL4A3 nephropathy.\",\n      \"method\": \"Transfection of podocytes with wild-type or mutant COL4A3; UPR pathway analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cell culture transfection with functional UPR readout; single lab, single method type\",\n      \"pmids\": [\"25514610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"COL4A3 expressed specifically in endothelial cells of Col4a3-/- mice (using an inducible endothelial-specific transgene) does not produce detectable collagen α3α4α5(IV) in the GBM and does not rescue the Alport phenotype, establishing that endothelial cells do not express the Col4a3/a4/a5 genes and are not a viable target for gene therapy.\",\n      \"method\": \"Endothelial cell-specific inducible transgenic expression in Col4a3-/- mice; immunofluorescence; phenotype assessment\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous negative result confirmed by immunofluorescence and phenotypic rescue failure; clear cell-type specificity established\",\n      \"pmids\": [\"30724107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A missense mutation in COL4A3 (p.G856Glu) was successfully reverted toward wild type in podocyte-lineage cells isolated from patient urine using CRISPR/Cas9 genome editing (>40% reversion, <15% indels), demonstrating that podocyte-lineage cells are the relevant cellular target for COL4A3 gene correction.\",\n      \"method\": \"CRISPR/Cas9 genome editing; mCherry/GFP reporter system; Sanger sequencing in patient-derived podocyte-lineage cells\",\n      \"journal\": \"European journal of human genetics : EJHG\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct genome editing in disease-relevant cells; single lab, single method; no long-term functional rescue shown\",\n      \"pmids\": [\"31754267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A COL4A3 frameshift mutation (c.4317delA) causing a truncated NC1 domain induces excessive endoplasmic reticulum stress and ER stress-mediated apoptosis in human podocytes. Proteasomal inhibition (MG132) increases intracellular accumulation of the truncated chain, worsening ER stress and apoptosis, identifying the proteasome as the primary degradation route for the misfolded mutant chain.\",\n      \"method\": \"Lentiviral stable transfection of human podocytes; RT-PCR; Western blot; pharmacological inhibition (MG132, brefeldin A); CRISPR/Cas9 KO podocytes\",\n      \"journal\": \"Chinese medical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in cell culture; single lab\",\n      \"pmids\": [\"31306228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A COL4A3 variant (8-residue appendage at C-terminus of the α3 subunit of the α345 hexamer) introduced as a knock-in in mice causes GBM abnormalities and proteinuria phenocopying Alport syndrome. Crystallography and assembly studies revealed hexamer mechanisms; bioactive sites on the hexamer surface converge pathogenic pathways of Goodpasture's and Alport syndrome.\",\n      \"method\": \"Knock-in mouse model; crystallography; hexamer assembly studies; immunostaining; functional proteinuria readout\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystallography plus knock-in mouse reconstitution; multiple orthogonal methods from one study\",\n      \"pmids\": [\"33774048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A knock-in mouse harboring Col4a3 p.Gly1332Glu recapitulates Alport syndrome features. In glomeruli, the mutant α3 chain and the normal α4/α5 chains appear to undergo proteolytic cleavage near the mutation site, producing a ~35 kDa C-terminal fragment, possibly mediated by MMP-9, while tubuli show reduced mutant collagen expression.\",\n      \"method\": \"Knock-in and compound heterozygous mouse models; Western blot; immunostaining; electron microscopy; serum urea/creatinine; MMP inhibitor inference\",\n      \"journal\": \"Matrix biology plus\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knock-in mouse with proteomic and EM readouts; MMP-9-mediated cleavage inferred from fragment size, not directly demonstrated\",\n      \"pmids\": [\"33718859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"COL4A3 expression in bronchial epithelium is negatively regulated by intronic DNA methylation (cg11797365); methylation at this site is increased by rhinovirus infection in vitro. ZNF263 binds this intronic region (by ChIP-seq), and ZNF263 silencing reduces COL4A3 expression, identifying an epigenetic/transcriptional mechanism controlling COL4A3 levels in airway epithelium.\",\n      \"method\": \"RNA-sequencing; DNA methylation bead arrays; ChIP-seq with qPCR; siRNA silencing of ZNF263\",\n      \"journal\": \"ERJ open research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq binding plus siRNA functional validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"34109240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZEB1 (TCF8) binds to six of nine E2-box motifs in the COL4A3 promoter (demonstrated by EMSA) and overexpression of ZEB1 reduces COL4A3 promoter activity in luciferase reporter assays, establishing ZEB1 as a direct transcriptional repressor of COL4A3.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA); dual-luciferase reporter assay; ZEB1 overexpression and truncation mutants\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct DNA-binding assay (EMSA) plus functional reporter assay; two orthogonal methods; consistent with earlier TCF8/PPCD finding\",\n      \"pmids\": [\"27537263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TCF8 (ZEB1) frameshift/nonsense mutations in PPCD3 families result in ectopic expression of COL4A3 in corneal endothelial cells, demonstrated by immunohistochemistry, and a TCF8 binding site (core plus secondary) was identified in the COL4A3 promoter, establishing TCF8 as a transcriptional repressor of COL4A3 whose loss causes aberrant COL4A3 expression.\",\n      \"method\": \"Mutation analysis; in silico promoter analysis; immunohistochemistry in corneal endothelium\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — IHC of ectopic protein expression combined with promoter binding site identification; mechanistic link inferred; direct binding not shown in this paper\",\n      \"pmids\": [\"16252232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"COL4A3 missense/synonymous variants p.(Leu1598Arg) and p.(Thr255Thr) were shown by in vitro minigene assay to alter RNA splicing—p.(Leu1598Arg) eliminates an alternative full-length transcript and p.(Thr255Thr) causes in-frame deletion of exon 13—demonstrating that exonic substitutions can pathogenically disrupt COL4A3 splicing.\",\n      \"method\": \"In vitro minigene splicing assay; Sanger sequencing; clinical segregation\",\n      \"journal\": \"Frontiers in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene functional assay directly demonstrates splicing disruption; single lab\",\n      \"pmids\": [\"35386907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A knock-in mouse bearing Col4a3 p.Gly799R shows pathological decrease in intracellular and secreted collagen IV α3α4α5 heterotrimers; mutant α3 chains accumulate in the ER and exhibit defective secretion, causing persistent ER stress and activating the MyD88/p38 MAPK pathway. Treatment with TUDCA (ER stress inhibitor) suppresses ER stress, promotes α3 chain secretion, and improves kidney function in vivo.\",\n      \"method\": \"Transgenic knock-in mouse; Western blot; immunofluorescence; RNA-seq; in vitro cell assays; pharmacological TUDCA treatment\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in model with RNA-seq, multiple molecular readouts, and pharmacological rescue; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"38782199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In podocytes and mice harboring COL4A3 p.C1616Y (murine p.C1615Y), microarray and validation experiments show upregulation of NOX4, H2O2, MMP-2, and apoptosis-related genes. NOX4 inhibition abrogates podocyte apoptosis and downregulates MMP-2 in vivo and in vitro; MMP-2 inhibition reduces apoptosis without affecting NOX4, placing COL4A3 mutation-induced podocyte apoptosis in a NOX4→MMP-2→apoptosis pathway.\",\n      \"method\": \"Microarray analysis on patient glomeruli; mutant human podocyte cell line; knock-in mice (p.C1615Y); NOX4 inhibitor (GKT137831) and MMP-2 inhibitor (SB-3CT); Western blot; immunohistochemistry; RT-PCR\",\n      \"journal\": \"Kidney international reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis by pharmacological inhibition in both in vitro and in vivo models, multiple orthogonal methods from a single rigorous study\",\n      \"pmids\": [\"37705901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Treatment of Col4a3 p.Gly1332Glu knock-in mice with 4-phenylbutyrate (4-PBA) improves secretion of mutant α3 chains and their incorporation into extracellular matrix (likely by enhancing trimer folding), reduces GBM lesions by 54%, decreases fibrosis and glomerulosclerosis, and maintains low proteinuria. In-vitro proteasomal inhibition in cultured podocytes confirmed that misfolded mutant collagen is degraded by the proteasome.\",\n      \"method\": \"Knock-in mouse model; electron microscopy; histology; proteasome inhibitor in primary podocytes; Western blot\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in-vivo pharmacological rescue plus in-vitro mechanistic validation; multiple orthogonal readouts from one rigorous study\",\n      \"pmids\": [\"40484355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Proteomic analysis of Col4a3-/- glomeruli revealed upregulation of vimentin (~2.5-fold by 2D-DIGE, ~5.4-fold by qRT-PCR) specifically in podocytes, as well as increased integrin α1 in mesangial cells and integrin α3 in podocytes, indicating that loss of the α3α4α5(IV) GBM network alters podocyte cytoskeletal and adhesion-receptor expression.\",\n      \"method\": \"2D-DIGE proteomics; mass spectrometry; qRT-PCR; quantitative confocal immunofluorescence; Col4a3-/- mouse model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — discovery proteomics confirmed by independent qRT-PCR and immunofluorescence; single lab\",\n      \"pmids\": [\"23236390\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COL4A3 encodes the α3 chain of type IV collagen that, together with α4 and α5 chains, assembles into the α3α4α5(IV) heterotrimer in the ER (requiring all three chains for network formation) and is secreted exclusively by podocytes into the glomerular basement membrane, where the network provides long-term filtration barrier integrity; pathogenic mutations cause defective heterotrimer assembly/secretion, ER stress with MyD88/p38 MAPK and UPR activation, proteasomal degradation of misfolded chains, and downstream podocyte apoptosis via a NOX4→MMP-2 pathway, while transcription of COL4A3 is negatively regulated by ZEB1/TCF8 binding to E2-box motifs in its promoter, and compensatory ectopic deposition of α5α6(IV) collagen can partially substitute for the absent network and delay renal failure.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"COL4A3 encodes the \\u03b13 chain of type IV collagen, an obligate building block of the \\u03b13\\u03b14\\u03b15(IV) heterotrimeric network that constitutes the mature glomerular basement membrane (GBM) filtration barrier [#0, #3]. Network assembly requires all three chains: knockout of COL4A3 eliminates \\u03b13, \\u03b14, and \\u03b15(IV) from the GBM and produces progressive glomerulonephritis with GBM multilamination and end-stage renal disease, while reintroduction of human \\u03b13(IV) restores co-assembly of the heterotrimer and rescues the phenotype [#0, #3]. COL4A3 and the adjacent COL4A4 are arranged head-to-head and share a bidirectional, TATA-less promoter, and both chains are independently required for GBM integrity [#1, #2]; transcription is directly repressed by ZEB1/TCF8 binding E2-box motifs in the promoter, loss of which drives ectopic \\u03b13(IV) expression in corneal endothelium [#17, #18]. The chains are deposited specifically by podocytes rather than endothelial cells, identifying the podocyte lineage as the relevant target for genetic correction [#11, #12]. Pathogenic COL4A3 mutations\\u2014including splice-altering, frameshift, and missense changes\\u2014cause autosomal recessive and dominant Alport syndrome by disrupting heterotrimer assembly and secretion [#5, #6, #19]; misfolded mutant \\u03b13 chains accumulate in the ER, are cleared by the proteasome, and trigger persistent ER stress that activates the unfolded protein response and the MyD88/p38 MAPK pathway, driving podocyte apoptosis and fibrosis [#10, #13, #20]. Downstream, mutation-induced injury proceeds through a NOX4\\u2192MMP-2 apoptotic pathway in podocytes [#21], while collagen-receptor signalling through integrin \\u03b12\\u03b21 drives fibrosis progression [#9]. Disease severity is modulated by compensatory ectopic deposition of \\u03b15\\u03b16(IV) collagen, which partially substitutes for the absent network and prolongs renal survival [#4]. Chemical chaperones (TUDCA, 4-PBA) that relieve ER stress and promote mutant chain secretion improve GBM lesions and kidney function, establishing the assembly/secretion defect as a tractable therapeutic target [#20, #22]. Absence of \\u03b13(IV) from the GBM also breaks immunological tolerance to the NC1 domain Goodpasture epitope, underlying post-transplant anti-GBM nephritis [#7, #8, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that COL4A3 is required to assemble the \\u03b13\\u03b14\\u03b15(IV) collagen network in the GBM, defining its core in-vivo function and the basis of Alport pathology.\",\n      \"evidence\": \"COL4A3 knockout mouse analyzed by immunofluorescence, TEM, and Northern blot\",\n      \"pmids\": [\"8956999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve whether \\u03b13/\\u03b14/\\u03b15 are co-dependent for assembly or whether each is individually required\", \"Cell-type source of the chains not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapped the COL4A3/COL4A4 head-to-head genomic arrangement and bidirectional TATA-less promoter, defining the transcriptional architecture controlling both chains.\",\n      \"evidence\": \"Genomic cloning, RACE, and RNase protection mapping of transcription start sites\",\n      \"pmids\": [\"9537506\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No trans-acting factors identified at this stage\", \"Tissue-specific regulation not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed both \\u03b13 and \\u03b14 chains are individually required for GBM integrity and that joint loss accelerates disease, confirming non-redundant roles via the shared promoter.\",\n      \"evidence\": \"Transgenic insertional knockout (OVE250) ablating the shared promoter, with RT-PCR, immunostaining, and EM\",\n      \"pmids\": [\"10534397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Insertional deletion removes regulatory elements as well as coding exons, complicating attribution\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated by transgenic rescue that providing \\u03b13(IV) restores heterotrimer co-assembly and reverses the Alport phenotype, proving defective assembly is the pathogenic mechanism.\",\n      \"evidence\": \"YAC transgenic rescue in Col4a3-/- mice with immunofluorescence and functional renal readouts\",\n      \"pmids\": [\"14507670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define cell-type of expression required for rescue\", \"Did not address mutant (vs absent) chain behavior\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified compensatory \\u03b15\\u03b16(IV) deposition as a strain-dependent modifier that partially substitutes for the lost network and prolongs survival, explaining phenotypic variability.\",\n      \"evidence\": \"Col4a3-/- mice across genetic backgrounds with immunofluorescence and survival analysis\",\n      \"pmids\": [\"16769745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger for the isoform switch unknown\", \"Human relevance of \\u03b15\\u03b16 substitution not established here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linked ZEB1/TCF8 to COL4A3 transcriptional repression, showing that loss of the repressor causes ectopic COL4A3 expression in corneal endothelium (PPCD3).\",\n      \"evidence\": \"TCF8 mutation analysis, promoter binding-site identification, and IHC of corneal endothelium\",\n      \"pmids\": [\"16252232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA binding not demonstrated in this study\", \"Mechanism inferred from IHC and in silico analysis\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Confirmed ZEB1 as a direct transcriptional repressor of COL4A3 by showing binding to E2-box motifs and repression of promoter activity.\",\n      \"evidence\": \"EMSA and dual-luciferase reporter assays with ZEB1 overexpression and truncation mutants\",\n      \"pmids\": [\"27537263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-vivo relevance to GBM regulation not tested\", \"Other E2-box factors not excluded\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended transcriptional control of COL4A3 to an epigenetic mechanism in airway epithelium, identifying intronic methylation and ZNF263 binding as regulators of expression.\",\n      \"evidence\": \"RNA-seq, methylation arrays, ChIP-seq, and ZNF263 siRNA silencing in bronchial epithelium\",\n      \"pmids\": [\"34109240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relevance to renal/GBM COL4A3 expression unclear\", \"Single-lab finding in non-renal tissue\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed integrin \\u03b12\\u03b21 collagen-receptor signalling as a driver of fibrosis progression downstream of GBM injury, identifying a modifiable disease pathway.\",\n      \"evidence\": \"Col4a3-/-/Itga2-/- double-knockout mice with EM, MMP/TIMP profiling, and survival readouts\",\n      \"pmids\": [\"24480069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type mediating integrin signalling not isolated\", \"Mechanism connecting integrin to MMP normalization not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Began defining how mutant \\u03b13 chains cause injury, showing intracellular retention and differential UPR activation in podocytes.\",\n      \"evidence\": \"Transfection of podocytes with mutant COL4A3 and UPR pathway analysis\",\n      \"pmids\": [\"25514610\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single method type in cell culture\", \"Causal link from UPR to phenotype severity not demonstrated in vivo\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established the podocyte lineage as the obligate source of \\u03b13(IV) and the relevant target for gene correction, while excluding endothelial cells.\",\n      \"evidence\": \"Endothelial-specific transgene failure to rescue Col4a3-/- mice; CRISPR/Cas9 reversion in patient urine-derived podocyte-lineage cells\",\n      \"pmids\": [\"30724107\", \"31754267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term functional rescue after CRISPR correction not shown\", \"Editing efficiency in vivo not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified the proteasome as the degradation route for misfolded mutant \\u03b13 chains and linked their accumulation to ER stress-mediated podocyte apoptosis.\",\n      \"evidence\": \"Lentiviral expression of truncated COL4A3 in human podocytes with MG132/brefeldin A inhibition and CRISPR KO\",\n      \"pmids\": [\"31306228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab cell-culture system\", \"Specific ER stress effectors not delineated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed in a knock-in model that mutant and partner chains undergo proteolytic cleavage producing a C-terminal fragment, implicating extracellular processing in pathology.\",\n      \"evidence\": \"Col4a3 p.Gly1332Glu knock-in mice with Western blot, immunostaining, EM, and MMP-inhibitor inference\",\n      \"pmids\": [\"33718859\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MMP-9 mediation inferred from fragment size, not directly demonstrated\", \"Functional consequence of the fragment unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved hexamer assembly mechanisms structurally and showed bioactive NC1 surface sites converge the pathogenic pathways of Goodpasture's and Alport syndromes.\",\n      \"evidence\": \"Knock-in mouse with C-terminal appendage, crystallography, and hexamer assembly studies\",\n      \"pmids\": [\"33774048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demonstration of autoantibody-triggering in vivo not part of this study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a NOX4\\u2192MMP-2\\u2192apoptosis pathway as the downstream effector of COL4A3 mutation-induced podocyte injury, identifying druggable nodes.\",\n      \"evidence\": \"Mutant human podocytes and p.C1615Y knock-in mice with NOX4 and MMP-2 inhibitors, microarray, and IHC\",\n      \"pmids\": [\"37705901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Connection between ER stress and NOX4 induction not fully mapped\", \"Generalizability across mutation classes not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked the secretion defect to a defined ER-stress signalling axis (MyD88/p38 MAPK) and demonstrated pharmacological rescue, establishing ER stress as a therapeutic target.\",\n      \"evidence\": \"Col4a3 p.Gly799R knock-in mice with RNA-seq, Western blot, immunofluorescence, and TUDCA treatment\",\n      \"pmids\": [\"38782199\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all mutation classes respond to ER-stress relief unclear\", \"Durability of TUDCA benefit not addressed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Confirmed that chemical-chaperone rescue (4-PBA) enhances mutant chain folding, secretion, and ECM incorporation, reducing GBM lesions and fibrosis.\",\n      \"evidence\": \"Col4a3 p.Gly1332Glu knock-in mice with EM, histology, and proteasome-inhibition validation in primary podocytes\",\n      \"pmids\": [\"40484355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mutation-class dependence of response not defined\", \"Translational dosing/safety not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How upstream ER stress signalling connects to the NOX4\\u2192MMP-2 apoptotic axis and to integrin-driven fibrosis, and which mutation classes are amenable to chaperone-based correction, remains to be unified.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No single model integrates ER stress, oxidative/MMP, and integrin pathways\", \"Predictors of therapeutic responsiveness across mutation types not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 3, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [10, 13, 20]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 3, 9]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [10, 13, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 6, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [17, 18]}\n    ],\n    \"complexes\": [\n      \"\\u03b13\\u03b14\\u03b15(IV) collagen heterotrimer\",\n      \"\\u03b1345(IV) NC1 hexamer\"\n    ],\n    \"partners\": [\n      \"COL4A4\",\n      \"COL4A5\",\n      \"ITGA2\",\n      \"DDR1\",\n      \"ZEB1\",\n      \"ZNF263\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}